US 11,666,590 B2
Pharmaceutical composition, methods for treating and uses thereof
Uli Christian Broedl, Oakville (CA); Odd-Erik Johansen, Hoevik (NO); Eric Williams Mayoux, Neauphle-le-Vieux (FR); Nima Soleymanlou, Maple (CA); Maximilian von Eynatten, Wiesbaden (DE); Hans-Juergen Woerle, Grandvaux VD (CH); David Z.I. Cherney, Toronto (CA); and Bruce A. Perkins, Toronto (CA)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Nov. 10, 2020, as Appl. No. 17/94,037.
Application 17/094,037 is a continuation of application No. 16/738,112, filed on Jan. 9, 2020, abandoned.
Application 16/738,112 is a continuation of application No. 16/131,165, filed on Sep. 14, 2018, abandoned.
Application 16/131,165 is a continuation of application No. 15/899,499, filed on Feb. 20, 2018, abandoned.
Application 15/899,499 is a continuation of application No. 15/672,517, filed on Aug. 9, 2017, abandoned.
Application 15/672,517 is a continuation of application No. 14/918,818, filed on Oct. 21, 2015, abandoned.
Application 14/918,818 is a continuation of application No. 14/253,935, filed on Apr. 16, 2014, abandoned.
Claims priority of provisional application 61/823,045, filed on May 14, 2013.
Claims priority of provisional application 61/813,223, filed on Apr. 18, 2013.
Prior Publication US 2021/0228610 A1, Jul. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7048 (2006.01); A61K 45/06 (2006.01); A61K 38/28 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/155 (2006.01); A61K 31/522 (2006.01)
CPC A61K 31/7048 (2013.01) [A61K 9/2018 (2013.01); A61K 9/2866 (2013.01); A61K 31/155 (2013.01); A61K 31/522 (2013.01); A61K 38/28 (2013.01); A61K 45/06 (2013.01)] 32 Claims
 
1. A method of treating, reducing the risk of, delaying the occurrence of and/or delaying the progression of chronic kidney disease in a patient, said method comprising administering to the patient a pharmaceutially effective amount of empagliflozin, optionally in combination with one or more other therapeutic substances.